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Triage strategiesBackground.With the implementation of primary high-risk human papillomavirus (hrHPV) screening in the
Netherlands, an increase was observed in the number of unnecessary referrals (≤Cervical Intraepithelial Neopla-
sia (CIN) 1) to colposcopy.We aimed to investigate which alternative triage strategies safely reduce unnecessary
referrals in HPV-based cervical cancer screening programmes.
Methods.MicrosimulationmodelMISCANwas used to simulate an unvaccinated cohort of tenmillion 30-year
old Dutchwomen. We calculated unnecessary referrals, cervical cancer incidence, mortality, costs and QALYs for
24 triage strategies. Condition for direct referral (atypical squamous cells of undetermined significance (ASC-US),
low-grade squamous intraepithelial lesions (LSIL), high-grade squamous intraepithelial lesions (HSIL), condi-
tional on HPV-genotype 16/18/other high risk (OHR)), type of triage test (cytology alone or combined with
hrHPV) and time to triage test (6 or 12 months) was varied.
Results. The 24 triage strategies had varying effects on the number of unnecessary referrals ranging from
−72% to +35%. Adjusting conditions for referral to ‘HPV16/18+ and ASC-US+’ and ‘HPVOHR+ and HSIL+’
and extending the interval between tests to 12months resulted in a reduction inunnecessary referrals of 40% (in-
cidence+0%,mortality−1%). Reduction in unnecessary referrals without genotypingwas achieved by adjusting
conditions for direct referral to LSIL (12 months to repeat test) (unnecessary referrals −37%, incidence +2%,
mortality +0%).
Conclusions. To reduce the number of unnecessary referrals without increasing incidence and mortality by
more than 2% in the Dutch cervical cancer screening programme, genotyping for HPV16 or HPV16/18 should
be implemented with 12 months to repeat testing.
© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Manyhigh-income countries have recentlymade the transition from
primary cytology screening to primary high-risk human papillomavirus
(hrHPV) DNA screening in their cervical cancer screening programmesHealth, office Na2401, Dr.
.
.
. This is an open access article under
ansen, C.A. Aitken, et al., Redu
c Oncology, https://doi.org/10[1–3]. In 2017, the Netherlands became the first country to implement
a national cervical cancer screening programme based on primary
hrHPV screening for all women, either by clinician-collected testing or
self-sampling, and reflex cytology triage. Women aged 30 to 60 years
are eligible for invitation. Women who test hrHPV-positive with
cytological abnormalities (atypical squamous cells of undetermined sig-
nificance (ASC-US) or higher) are referred to the gynaecologist, and
hrHPV-positive women without cytological abnormalities are invited
for a repeat cytology test after six months.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
cing unnecessary referrals for colposcopy in hrHPV-positive women
.1016/j.ygyno.2020.12.038
S. Kaljouw, E.E.L. Jansen, C.A. Aitken et al. Gynecologic Oncology xxx (xxxx) xxxNot all women who are referred from cervical cancer screening
programmes require treatment because low-grade lesions (< CIN 2)
can regress without intervention. These women are unnecessarily re-
ferred. The first results of the hrHPV screening programme showed
that the number of unnecessary referrals to the gynaecologist increased
after implementation [4], which confirmed model estimates from prior
to the programme's implementation [5]. Increases in unnecessary refer-
rals can lead to increased costs and colposcopy capacity problems [6]. It
can also be distressing and cause anxiety for women [7]. Additionally,
unnecessary treatment of detected regressive or non-progressive pre-
invasive lesions, can cause physical distress, such as pain, bleeding,
and discharge, and has been associated with preterm births [8]. There-
fore, limiting unnecessary referrals and treatment can reduce harms re-
lated to treatment. Following the successful implementation of the
programme in the real-life setting, reducing the number of unnecessary
referrals was identified as the first opportunity to optimise the new
screening programme.
Currently available technologies that can be used to optimise the tri-
age algorithm, as a fast and easy way to achieve a reduction in unneces-
sary referrals, are 1) adding genotyping to the triage algorithm,
2) changing the cytology cut-off for direct referral (LSIL instead of
ASC-US), and 3) lengthening the time to repeat cytology testing. The lat-
ter is based on the fact that most hrHPV infections regresswithin one to
two years [9], which means that most infections are probably not yet
regressed within 6 months (i.e. the current repeat interval). However,
the impact of these potential changes on unnecessary referrals and cer-
vical cancer epidemiology has not yet been quantified.
We aimed, using microsimulation modelling, to identify a triage
strategy which results in a quickly achievable reduction of the number
of unnecessary referrals, without increasing cervical cancer incidence
and mortality beyond what is considered acceptable. We calculated
the effects of implementing the following possible options (or combina-
tions thereof): adding genotyping on HPV16 or HPV16/18; adding a re-
peat hrHPV test; increasing time to repeat test, and; changes to the
referral threshold after the baseline cytology test.
2. Methods
In order to estimate the costs and health effects of different triage
strategies, we conducted analysis using the MISCAN-Cervix
microsimulation model. MISCAN-Cervix is a well-documented semi-
Markov microsimulation software program. We used the recently cali-
brated version of MISCAN-Cervix described previously by Jansen,
Naber [6].
2.1. MISCAN-Cervix model
MISCAN-Cervix generates a large hypothetical populationwith indi-
vidual life histories. For this study, we simulated a cohort of ten million
unvaccinated 30-year-old women based on Dutch demographic [10]
and hysterectomy data [11]. Women in the simulated population can
acquire one or more hrHPV infections during their life. These infections
are categorised in four groups, based on their oncogenicity and their
presence in different vaccine types (i.e. the bi-, quadri-, and nonavalent
vaccine). These groups are (1) HPV-16, (2) HPV-18, (3) Other high risk
HPV types (HPV-OHR; HPV-31/33/45/52/58/35/39/51/56/59/66/68). In
MISCAN-Cervix, a distinction is made between HPV-31/33/45/52/58
and HPV-35/39/51/56/59/66/68, but results for these two groups are
presented together in this study. The infection either clears or leads to
the development of pre-invasive cervical lesions. These lesions can ei-
ther regress or develop into invasive cervical cancer, classified in FIGO
(International Federation of Gynecology and Obstetrics) stages 1A, 1B,
2, 3, and 4. In the model, death can occur from cervical cancer or from
other causes. Multiple infections can occur at the same time, which
are independent of each other. Interventions such as hysterectomy,
treatment, and screening can affect these life histories. Pre-invasive2
stages and FIGO 1A cases can only be detected by screening, as these
are assumed to be asymptomatic, whereas FIGO 1B or worse can also
be clinically diagnosed.
2.2. Disease development
The model divides cervical disease into nine sequential stages:
hrHPV infection, three pre-invasive stages (CIN grade 1, 2, and 3), and
five invasive stages (FIGO stages 1A, 1B, 2, 3, and 4). The risk of acquiring
an hrHPV infection is age- and type-specific. In themodel, most HPV in-
fections are transient. Lesions in pre-invasive stages can also regress.
While pre-invasive lesions can develop without an HPV infection (in
which case they will always regress in our model), cervical cancer can
only develop in the presence of a hrHPV infection. The durations of
HPV infections as well as most pre-invasive and invasive cancer stages
are modelled as exponential distributions with different average dura-
tions, as shown in Table 1.
To account for different cancer risk levels for different HPV geno-
types, the progression probabilities for the different health stages are
dependent on the genotype of the HPV infection [see Appendix A].
The progression probabilities per group of HPV genotypes were found
through calibration. Progression probabilities for an HPV-16 infection
are higher than average for all lesion grades, whereas those for an
HPV-35/39/51/56/59/66/68 infection are lower for all lesion grades.
ForHPV-18 infections, theprogression probabilities are generally higher
than those of HPV-31/33/45/52/58 infections, although this does de-
pend on the lesion grade [6].
2.3. Test characteristics
The test characteristics for cytologywere calibrated based on CINde-
tection rates and interval cancers between 2004 and 2013 (Table 1). The
test characteristics for theHPV testwere based on literature [12,13]. The
test characteristics for the HPV self-test were assumed to be equal to
those of the regular HPV test. Furthermore, the sensitivity of colposcopy
is assumed to be 100%.
2.4. Triage strategies
We estimated the costs and health effects of 24 different triaging
strategies (including the current triage strategy; Fig. 1)). These were
subdivided into six categories. Table 2 contains information about all
24 strategies. Visual representations of the six categories of strategies
can be found in Appendix B. For each category of strategies, we esti-
mated effects based on both a six-month period and a 12-month period
to repeat testing.
The first alternative strategy is to extend the time to repeat cytology
(TTR) from 6months to 12months (Strategy name: ‘12mthTTR’). In the
second category, we added an HPV test to the repeat test after six
months. In this strategy, the repeat test for HPV positive, cytology neg-
ative women consists of an HPV test first and a cytology reflex test if
the HPV test is positive. If both are positive, women are referred for col-
poscopy (Strategy names: ‘ExtraHPV’, ‘ExtraHPV-12mthTTR’).
For the third category of triage strategies, we increased the referral
threshold after the reflex cytology to either low-grade squamous
intraepithelial lesion (LSIL) or high-grade squamous intraepithelial le-
sion (HSIL) (Strategy names: ‘CytLSIL’, ‘CytHSIL’, ‘CytLSIL-12mthTTR’,
‘CytHSIL-12mthTTR’).
The fourth category is a combination of the second and third
category: An HPV test was added to the repeat test after six months
and the referral threshold after the initial reflex cytology was increased
to LSIL or HSIL, respectively (Strategy names: ‘ExtraHPV-CytLSIL’,
‘ExtraHPV-CytHSIL’,‘ExtraHPV-CytLSIL-12mthTTR’,‘ExtraHPV-CytHSIL-
12mthTTR’.)
In the fifth category, the initial triage of hrHPV-positive women was
based on both the cytology result and the hrHPV genotype. We
Table 1
Average sojourn time until progression or regression and cytology/HPV test characteristics per stage.
Probability of a positive test result
HPV infection present Disease status Mean duration (Weibull distribution) Cytology ≥ASC-US** Cytology ≥HSIL** Positive hrHPV-test***
≥1 HPV infection no CIN present 1 year [29,30] 17.1% 0.0% 55.0%
≥1 HPV infection CIN1 1.5 years [31] 36.2% 2.6% 72.0%
≥1 HPV infection CIN2 2 years [31] 37.1% 10.7% 94.0%
≥1 HPV infection CIN3 14.3/5.7 years*ª 75.4% 51.6% 94.0%
≥1 HPV infection FIGO 1A 4 yearsª 85.1% 64.7% 94.0%
≥1 HPV infection FIGO 1B 2.2 yearsª 85.1% 64.7% 94.0%
≥1 HPV infection FIGO 2 1.7 yearsª 85.1% 64.7% 94.0%
≥1 HPV infection FIGO 3 1.7 yearsª 85.1% 64.7% 94.0%
≥1 HPV infection FIGO 4 0.7 yearsª 85.1% 64.7% 94.0%
No HPV no CIN present – 0.6% 0.04% 0.0%
No HPV CIN1 1.5 years [31] 36.2% 2.6% 0.0%
No HPV CIN2 2 years [31] 37.1% 10.7% 0.0%
No HPV CIN3 14.3/5.7 years*ª 75.4% 51.6% 0.0%
ª Calibrated in MISCAN-cervix.
* Progressive CIN 3/Regressive CIN 3.
** Probability to test positive the first time a women with this lesion present attends screening. 12% of the CIN lesions will be missed systematically over time.
*** The same test characteristics are assumed for GP smears as for self-sampling kits.
hrHPV = high-risk human papillomavirus; CIN = cervical intraepithelial neoplasia; ASC-US = Atypical squamous cells of undetermined significance; LSIL = Low-grade squamous
intraepithelial lesion; HSIL = High-grade squamous intraepithelial lesion, FIGO = International Federation of Gynecology and Obstetrics.
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or HPV18 were referred as usual, but women who were HPV-OHR
positive were only directly referred if they had at least an LSIL or HSIL
cytology result. In two additional similar scenarios, only women with
HPV16 were referred as usual (Strategy names: ‘16/18+ASC-US+/
OHR+LSIL,’ ‘16/18+ASC-US+/OHR+HSIL’, ‘16/18+ASC-US+/
OHR+LSIL-12mthTTR’, ‘16/18+ASC-US+/OHR+HSIL-12mthTTR’,
‘16+ ASC-US+/OHR+LSIL’, ‘16+ASC-US+/OHR+HSIL’, ‘16+ASC-
US+/OHR+LSIL-12mthTTR’, ‘16+ASC-US+/OHR+HSIL-12mthTTR’).
Finally, in the sixth category we simulated one scenario in which
womenwhowere positive for HPV16were referred to the gynaecologist
directly, without cytological testing. The remaining hrHPV-positive
women were only referred if they had at least an HSIL cytology result.
In another scenario, women with HPV18 were referred directly as well,
irrespective of the cytology result (Strategy names: ‘16/18+/OHR+LSIL’,
‘16/18+/OHR+HSIL’, ‘16/18+/OHR+LSIL-12mthTTR’, ‘16/18+/
OHR+HSIL-12mthTTR’).Fig. 1. Current HPV-based screening and triage algorithm.HPV−/+: negative/positive result of H
intraepithelial lesion or malignancy, M/Y: months/years. NB: Primary screening could be con
negative at age 60 exit the programme and do not receive another screening invitation.
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2.5. Key outcomes
Outcomes of interest are the number of unnecessary referrals, cervi-
cal cancermortality, cervical cancer incidence, total costs and number of
lost quality-adjusted-life-years (QALYs). We defined clinically relevant
lesions as being CIN 2 or higher, meaning all referrals resulting in a diag-
nosis of lower than CIN 2were considered unnecessary.We calculated a
woman's QALYs by subtracting disutilities caused by either screening-
related events or due to disease from the total number of life-years
lived. The values of the disutilities are determined by the duration of
the event and a weight reflecting the severity of the event. We used a
similar approach to determine the total costs of screening; for each
screening- or disease-related event, there are associated costs which
are summed over the lifetime of all simulatedwomen. The assumptions
for QALYs and costs can be found in Appendix C. All outcomes are pre-
sented per 100,000 30-year-old women followed lifelong. Suitable
strategies are defined as thosewhich result in a decrease in unnecessaryPV test, ASC-US: Atypical squamous cells of undetermined significance, NILM: Negative for
ducted by a general practitioner or by using a self-sampling kit. Women who are hrHPV-
Table 2
Strategies based on months to repeat test, repeat test type and direct referral conditions. Strategy 1.1 is the current strategy.
Category Strategy Triage interval (months) Triage tests Direct referral conditions
1 1.1; 1.2 6; 12 Cytology HPV positive, ASC-US+
2 2.1; 2.2 6; 12 hrHPV, Cytology HPV positive, ASC-US+
3 3.1; 3.2 6; 12 Cytology HPV positive, HSIL+
3 3.3; 3.4 6; 12 Cytology HPV positive, LSIL+
4 4.1; 4.2 6; 12 hrHPV, Cytology HPV positive, HSIL+
4 4.3; 4.4 6; 12 hrHPV, Cytology HPV positive, LSIL+
5 5.1; 5.2 6; 12 Cytology HPV16/18 positive, ASC-US+ or
other hrHPV positive, HSIL+
5 5.3; 5.4 6; 12 Cytology HPV16/18 positive, ASC-US+ or
other hrHPV positive, LSIL+
5 5.5; 5.6 6; 12 Cytology HPV16 positive, ASC-US+ or
other hrHPV positive, HSIL+
5 5.7; 5.8 6; 12 Cytology HPV16 positive, ASC-US+ or
other hrHPV positive, LSIL+
6 6.1; 6.2 6; 12 Cytology HPV16/18 positive or other hrHPV positive, HSIL+
6 6.3; 6.4 6; 12 Cytology HPV16 positive or other hrHPV positive, HSIL+
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tality. We allowed for an increase up to 2% to account for random vari-
ation in model outcomes.
2.6. Base case analysis
In the base case analysis, we assumed attendance rates of primary
screening and adherence to repeat testing and colposcopy referral to be
100%. In this way, we tailor the triage strategy to women who attend the
screening programme and we avoid unnecessary screening of these
women. In addition,we applied disutilities from screening and colposcopy
referrals as reported in the Dutch utility study by de Kok, Korfage [14].
2.7. Sensitivity analyses
In univariate sensitivity analyses, we varied several uncertain pa-
rameters to investigate their influence on the model outcomes. For
screening behaviour, we performed three different sensitivity analyses
(details can be found in Appendix D). First, we assumed attendance
and adherence as observed in 2017 in the Netherlands in order to get
an estimate of how each strategy would perform in the context of cur-
rent screening attendance rates [6]. Secondly, we used the attendance
and adherence as observed in 2017, but we decreased the adherence
for the repeat test to 69% if the time to repeat test was increased to
12 months, based on the participation for triage cytology after
12 months in the old Dutch cytology-based programme [15]. As a
third scenario, we applied the attendance rates as observed in
2014–2016 in the Netherlands, when a cytology-based screening algo-
rithm was used. In this period the attendance and adherence were
somewhat higher than in 2017 (assuming that in the future the atten-
dancewill return to the previous rates again) [4]. In the second sensitiv-
ity analysis we used alternative disutility assumptions [16,17]. In the
third sensitivity analysis, we increased sensitivity of the cytology test
after a positive HPV test by 50% for CIN 1 and CIN 2 as compared to
the test characteristics in the base case analysis. Higher sensitivity has
been measured when the cytology test is used as a reflex or repeat
test as compared to use as a primary test [18]. Lastly, we considered
the effect of a change in the outcomemeasure by increasing the thresh-
old for clinically relevant lesions from CIN 2 to CIN 3.
2.8. Patient and public involvement
This research was done without patient involvement. Patients were
not invited to comment on the studydesign, interpret the results or con-
tribute to writing or editing of this document. We do not intend to dis-
seminate our results to patients or women eligible for screening.4
3. Results
3.1. Base case analysis
The current screening programme resulted in 361 cancer diagnoses,
74 cervical cancer deaths and 19,838 unnecessary referrals per 100,000
women (Table 3). The strategies with direct referral for HPV16 or
HPV16/18 positive women (category 6) cause an increase in unneces-
sary referrals (Fig. 2). Therefore, this category of strategies does not
meet the defined criteria of a preferred strategy. Furthermore, all the
strategies where the cytology referral threshold is increased
(‘(ExtraHPV-)CytLSIL/HSIL’, category 3 and 4) cause a relatively large in-
crease in mortality and incidence. Therefore, these strategies are also
not preferred. One exception is the strategywhere the referral threshold
is increased to LSIL and the time to repeat testing is extended to
12 months (‘CytLSIL-12mthTTR’, Table 2 (3.4)). Lastly, the strategy
where the referral threshold is increased to HSIL for all HPV-positive
women who do not have HPV-16 with six months to repeat test
(‘16+ASC-US+/OHR+HSIL’, Table 2 (5.5)), causes an increase in both
incidence and mortality of slightly more than 2% and is therefore ex-
cluded from the preferred strategies. Fig. 2 also shows that only extend-
ing the time to repeat test to 12months (‘12mthTTR’, Table 2 (1.2)) does
not increase the incidence of or mortality from cervical cancer. On the
contrary, it decreases incidence and mortality (−1.2% and −1.7%, re-
spectively, Table 3) while also reducing the number of unnecessary re-
ferrals. In general, strategies with 12 months to repeat test result in a
larger reduction of unnecessary referrals than strategies with 6 months
to repeat test without deteriorating mortality or incidence.
The largest reductions in unnecessary referrals without substantial
increase in mortality or incidence are achieved by genotyping for
HPV16 (−45%, ‘16+ASC-US+/OHR+HSIL-12mthTTR’ (5.6)) or
HPV16/18 (−40%, ‘16/18+ASC-US+/OHR+HSIL-12mthTTR’ (5.2))
while allowing direct referral for HPV-OHR with HSIL+ cytology, with
time to repeat test set to 12months.Without genotyping, the largest re-
duction (−37%) in unnecessary referrals is achieved by increasing the
threshold for direct referral from ASC-US to LSIL while setting time to
repeat test to 12 months (‘CytLSIL-12mthTTR’ (3.4)).
As expected, we found that the total cost of the screening pro-
gramme decreases linearly with the decrease in unnecessary referrals
(Fig. 3). Finally, the QALYs lost increase linearly with the decrease in un-
necessary referrals, as the number of repeat tests increases (Fig. 3).3.2. Sensitivity analysis
A detailed overview of the results of the sensitivity analyses can be
found in Appendix D. We found that the results of the study are
Table 3
Percentage change in unnecessary referrals, mortality, incidence, costs and QALYs lost for selected strategies.
Nr. Strategy name⁎ Unnecessary Referrals Mortality Incidence Costs (€) QALYs lost
1.1 Current 19,838 74 361 61,458,537 2591
1.2 12mthTTR % -7% -2% -1% -1% 28%
2.1 ExtraHPV % −12% 1% 1% −1% 1%
2.2 ExtraHPV-12mthTTR % −17% −1% −1% −2% 29%
3.4 CytLSIL-12mthTTR % −37% 0% 2% −5% 40%
5.1 16/18+ASC-US+/OHR+HSIL % −32% 1% 2% −4% 6%
5.2 16/18+ASC-US+/OHR+HSIL-12mthTTR % −40% −1% 0% −6% 39%
5.3 16/18+ASC-US+/OHR+LSIL % −19% 1% 1% −2% 3%
5.4 16/18+ASC-US+/OHR+LSIL-12mthTTR % −26% −2% −1% −3% 34%
5.6 16+ASC-US+/OHR+HSIL-12mthTTR % −45% 0% 2% −7% 42%
5.7 16+ASC-US+/OHR+LSIL % −21% 1% 1% −3% 4%
5.8 16+ASC-US+/OHR+LSIL-12mthTTR % −29% −1% 0% −4% 35%
⁎ Strategies are only included if they increase cervical cancer incidence and mortality with at most 2%. The values of the current strategy are presented per 100,000 women.
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sensitivity analyses we have done for attendance and adherence have
caused a shift in the preferred strategies.
The number of QALYs lost decreased significantlywhen applying the
alternative set of assumptions for disutilities due to screening and treat-
ment [16,17]. This effect is especially large for strategies with twelve
months to repeat testing.
We found that the results of this study are robust to the described
increases in sensitivity of the cytology test. The changes made have
no substantial effect on the number of unnecessary referrals, mortal-
ity from or incidence of cervical cancer. Lastly, we found that the
strategies based on genotyping result in a slightly larger reduction
in unnecessary referrals, compared to the other strategies, when in-
creasing clinical relevance from CIN2+ to CIN3+ due to the higher
prevalence of HPV16 in this group. However, we did not find a
change in preferred strategies.Fig. 2. Reduction in unnecessary referrals plotted against incidence and mortality for all 24 strategi
strategy. The dotted vertical line represents the 2% cut-off for mortality and incidence. Strategi
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4. Discussion
The aim of this studywas to identify a triage strategy that results in a
quickly achievable, safe reduction of the number of unnecessary refer-
rals for colposcopy in the Dutch hrHPV-based cervical screening pro-
gramme. We found that changing the conditions for referral based on
HPV 16/18 genotyping resulted in a substantial reduction in unneces-
sary referrals without increasing mortality or incidence. Similar results
were also found by increasing the threshold for direct referral to LSIL
for all HPV genotypes. For all strategies, 12 months to repeat test, com-
pared to sixmonths, resulted in the largest reduction in unnecessary re-
ferrals. Univariate sensitivity analyses showed that the results are
robust to changes in attendance, test characteristics, and clinical rele-
vance threshold.
In the base case analysis, we found that the number of QALYs lost
increases substantially when the number of unnecessary referralses (per 100,000 women). The vertical and horizontal solid lines represent the current triage
es on the left of this line and above the horizontal line are considered preferred.
Fig. 3. Reduction in unnecessary referrals plotted against total costs and QALYs lost for all 24 strategies (per 100,000 women). The vertical and horizontal solid lines represent the current triage
strategy. The dotted vertical line represents a 2% increase in total cost or QALYs lost.
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ber of referrals results in more women being advised to have repeat
testing. In our base-case disutility set, repeat testing has a higher disutil-
ity weight than referral. Secondly, increasing the time to repeat testing
from 6 months to 12 months amplifies this effect while decreasing the
number of referrals, since the disutility is applied for a longer period
[14]. When using a different set of disutility assumptions, the number
of QALYs lost were lower, because a longer period of uncertainty dis-
tressed women who were surveyed less [16,17]. Given the large varia-
tion in women's preference, we decided not to focus on QALYs lost as
a main outcome measure, instead focusing on outcomes that could be
measured more objectively.
The HPV16/18 genotyping strategies resulted in a large reduction in
unnecessary referrals without increasing mortality or incidence. This is
explained by the fact that 70 to 76% of cervical cancers worldwide are
caused by these two types of hrHPV infections [19]. By only raising the
referral threshold for the remaining hrHPV types, the number of unnec-
essary referrals decreases without a large increase in the risk of leaving
progressive lesions undetected. An increase in the time to repeat test
also has a positive impact on the unnecessary referrals. An explanation
for this is that a longer time to repeat test allows the HPV infection to
clear, since cervical cancer is a relatively slow growing cancer.
Our study has several strengths. All simulations were done with a
validated model, which used data directly observed from the new
hrHPV-based screening programme as input. MISCAN-Cervix is a well-
used, published microsimulation model, which is used in comparative
modelling studies and uses input values taken from observed data and
from the peer-reviewed literature. Moreover, we evaluated many strat-
egies that are easy to implement. This makes the results of the study di-
rectly applicable and relevant for practice in many countries that
consider implementing primary HPV screening. In addition, in sensitiv-
ity analyses we considered a wide range of different values for adher-
ence, two sets of disutility assumptions and two sets of test6
characteristics for cytology. As the conclusions of the study did not
change with these sensitivity analyses, we can conclude that the results
of this study are robust to changes in assumptions.
Our study also has some limitations. There are a few alternative
triaging methods that we did not consider, such as personalised
(based on previous screen test results) screening strategies, co-testing,
and new technologies. A Dutch study found women are at higher risk
of a CIN 3+ lesions in the years following a hrHPV-positive screen,
even if they have a hrHPV-negative screen in the subsequent screening
round [20], suggesting that personalised screening strategies based on
factors like screening historymay be beneficial. This was not considered
as a viable option for triage optimisation at this time due to logistical
reasons. Although co-testing is common practice in several Western
countries, it has been found to be inefficient in modelling studies [21]
and, thus, was not considered. New technologies such as methylation,
dual staining for p16/Ki67 or HPV E6/7 mRNA testing have been
shown to be promising triage options, with better sensitivity and spec-
ificity than cytology only [22–25]. However, these technologies are still
under investigation and not ready to implement in a running pro-
gramme. Furthermore, implementing these technologies would require
infrastructural changes to be made, such as extra training for
cytotechnicians and pathologists, as well as changing screening labora-
tory workflow. Given our aim was to find an alternative triage strategy
that could be rapidly implemented, these technologies were not consid-
ered. Finally, the quality of a model is always dependent on the data
used and the assumptions made. However, in the Netherlands, we
have a population-based registry that contains data on all screening-
indicators that we use for development of the model. Still, the assump-
tions for participation, test characteristics and disutilities are less certain
when making changes to the screening programme that are not imple-
mented yet (i.e. no observed data yet). We performed sensitivity analy-
sis on the parameters that aremost uncertain, to show the robustness of
the results and found that they did not change our conclusions.
S. Kaljouw, E.E.L. Jansen, C.A. Aitken et al. Gynecologic Oncology xxx (xxxx) xxxThis is the first study to compare so many strategies for triaging
hrHPV-positive women in order to investigate unnecessary referrals ver-
sus cancer incidence and mortality. A smaller study has previously been
published, which focused on determining the optimal triage strategy for
a smaller subgroup of HPV-OHR positive women [26]. They found that,
for HPV-OHR positive women who had low-grade cytology, 12 month
follow-up was the most cost-effective triage option, as it balanced the
benefits of surveillance with harms of unnecessary referrals. For the
group with high-grade baseline cytology, on the other hand, it was
found to be cost effective to advise direct referral to colposcopy.While di-
rect comparison with these results is difficult, our study also found that
risk stratification by HPV type and cytology grade are important for find-
ing the optimal triage strategy for different groups of women.
We found that genotyping based on HPV-16/18 can improve the ef-
ficiency of triaging HPV-positive women. The same conclusion was
reached by a recent data study on the implementation phase of the
hrHPV-based screening programme in Norway, where CIN3+ risk was
estimated for cytology results and HPV genotypes. By inviting women
with HPV-OHR and low-grade cytology for a repeat test instead of refer-
ring thesewomen for colposcopy, the harms and benefits of the screen-
ing programme were found to be more balanced [27].
Internationally, the reduction in unnecessary referrals that can be
achieved by implementing HPV 16/18 genotyping should encourage
policymakers to consider hrHPV testing systems that allow for this fea-
ture; at a minimum, screening programme managers should consider
the availability of systems that can distinguish HPV16 and HPV18
from HPV-OHR. Of course, policymakers need to evaluate the needs
and requirements of their own settings prior to implementing a test sys-
tem, but in the decision-making process, hrHPV genotyping should be
considered as a possible addition to new HPV-based cervical cancer
screening programme algorithms.
From 2023, the first cohort of women that were eligible for HPV vac-
cination will enter the screening programme in the Netherlands. Al-
though our study did not include vaccinated women within the
simulated cohort, this important change to the eligible populationwill ne-
cessitate reassessment of the triage algorithm in the coming decade.
Women vaccinated with a bivalent vaccine are protected against HPV16
andHPV18 infections, which has been shown in other countries to reduce
risk of CIN lesions amongst both vaccinated and unvaccinated women
(protected byherd immunity effects) [28].Without amore efficient triage
strategy, such as genotyping, vaccinatedwomenmay bemore likely to be
unnecessarily referred to the gynaecologist. The balance between harms
and benefits of screening for vaccinatedwomen could be improved by in-
cluding genotyping on HPV16/18 in the triage strategy.
5. Conclusion
This study aimed to identify a triage strategy that results in a quickly
achievable reduction of the number of unnecessary referrals with the
Dutch cervical cancer screening programme, without deteriorating
mortality from and incidence of cervical cancer. It is the first study
where such a wide range of strategies is modelled to find the best strat-
egy for all HPV positive women. We found that adding genotyping for
HPV16 and/or HPV18 to the referral algorithm while increasing the re-
ferral threshold for HPV-OHR to HSIL substantially decreases the num-
ber of unnecessary referrals without increasing cervical cancer
incidence or mortality. Extending the time to repeat testing from six
to 12months also reduced unnecessary referrals. Based on our findings,
we recommend implementing genotyping as a triage strategy for HPV-
positive women in the Dutch cervical cancer screening programme,
with possible extension of the time to repeat testing.
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